Literature DB >> 21966857

[Epidemiological profile of ovarian cancer].

Luz María Rivas-Corchado1, Manuel González-Geroniz, Ricardo Jorge Hernández-Herrera.   

Abstract

BACKGROUND: In Mexico, ovarian cancer represents 5.3% of cancer diagnoses in all age groups and 21% of gynecologic cancers. The states with the highest incidence of this disease Nuevo León, Mexico State and Federal District.
OBJECTIVE: To determine the epidemiological profile of ovarian cancer. PATIENTS AND METHODS: A retrospective cross-sectional study that included all patients with complete records, diagnosed with ovarian cancer treated at the Oncology department UMAE Monterrey No. 23, January 2009 to 31 December 2009.
RESULTS: We identified 40 patients with ovarian cancer. The average age of menarche was 12.7 years, 40% were of reproductive age, 25% were nulliparous, 15% had a pregnancy and 37.5% had two pregnancies. Of the total patients, 17% had a history of breast cancer, 40% used a contraceptive method, 37% used oral contraceptives. The tumor marker CA 125 was found in 40% of patients, 63.1% had ultrasound markers for cancer. The most frequent clinical stage 1A in which they found 32% of cases. Papillary serous adenocarcinoma was diagnosed in 25% of patients, endometroid adenocarcinoma and mucinous tumor of low malignant potential was diagnosed borderline at 20%, poorly differentiated adenocarcinoma in 18% tumor granulosa cells in 7% and papillary adenocarcinoma ring cell adenocarcinoma in 5%. In total, 43% of patients received chemotherapy.
CONCLUSION: The majority of cases tenia50 years or more. The background was the most frequent hereditary breast cancer. There were no deaths during the study.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21966857

Source DB:  PubMed          Journal:  Ginecol Obstet Mex        ISSN: 0300-9041


  1 in total

Review 1.  Evaluation of Ovarian Neoplasms in Honduras: Characteristics and Diagnostic Concordance Between Ultrasound, Tumor Markers and Histopathology.

Authors:  Ashley S Moon; Andrea Bourdeth; Roberto Jerez; Jackeline Alger; Linus Chuang
Journal:  Gynecol Oncol Rep       Date:  2019-10-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.